Research peptides in the United Kingdom: medicines by presentation or by function

In the United Kingdom a research peptide becomes a medicine in one of two ways: when someone presents it as having properties against disease, or when it does enough to the body, at the amount sold, to count as modifying a physiological function. The first test is about words and packaging. The second is about pharmacology. Both come from the European definition that Britain kept after leaving the European Union, both are applied case by case by the Medicines and Healthcare products Regulatory Agency, and in April 2026 the agency said in public what the two tests mean for a vial labeled "research only" and sold with a list of benefits: it is a medicine, unlicensed, and the clinic selling it will be investigated. This page sets out the law, how the MHRA applies it, the twenty-year enforcement record on peptides in the United Kingdom, and where a research peptide with no claims attached actually stands.

The statute: Human Medicines Regulations 2012

Regulation 2(1) of the Human Medicines Regulations 2012 defines a medicinal product as any substance or combination of substances presented as having properties of preventing or treating disease in human beings, or any substance or combination of substances that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action, or making a medical diagnosis. The two limbs are known as presentation and function. A product need satisfy only one.

Once a peptide is a medicinal product, three rules follow. Regulation 46(1): A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product. A medicine may be sold only under a UK marketing authorisation or one of a short list of registrations, with exceptions for clinical trials, export and the unlicensed "specials" route for a named person's special need. Regulation 279: a person may not advertise a medicinal product in Great Britain unless it holds a marketing authorisation. And the Regulations regulate sale, supply, manufacture, import for sale and advertising, not possession: a person who buys a peptide for their own use commits no offence under them. That last point is the structural difference between the United Kingdom and Australia, and it explains why British enforcement falls entirely on sellers, clinics and importers for sale.

No peptide of the research kind holds a UK marketing authorisation. BPC-157, TB-500, GHK-Cu, CJC-1295, ipamorelin, melanotan II and the rest are, if they are medicines at all, unlicensed medicines, and regulation 46 forbids their sale.

How the MHRA decides a research peptide is a medicine

The agency's Guidance Note 8, A guide to what is a medicinal product, explains how the two limbs are applied. On presentation, the MHRA considers, in context, any claims (implicit as well as explicit) which are made for it, and the characteristics of its presentation as a whole, and follows the Court of Justice in Van Bennekom: a product is presented as a medicine whenever any averagely well-informed consumer gains the impression, which provided it is definite, may even result from implications, that the product in question should, regard being had to its presentation, have an effect of the medicinal kind. The guidance lists wordings it regards as implied medicinal claims. One of them is Medical research..., which it describes as An implied claim to efficacy as a medicine. A page that recites what a peptide did in published studies is, to the MHRA, making a claim.

On function, the guidance follows HLH Warenvertriebs: the authority must proceed on a case by case basis, taking account of all the characteristics of the product, in particular its composition, its pharmacological properties, to the extent to which they can be established in the present state of scientific knowledge, the manner in which it is used, the extent of its distribution, its familiarity to consumers and the risks which its use may entail. The question is whether the product has significant effect on human physiology at the amount sold; a substance with a slight effect is not a medicine by function (Hecht-Pharma, 2009). Where that is in doubt, the MHRA will seek the advice of its medical and pharmaceutical assessors. The guidance also applies Article 2(2) of the Directive: where a product could be a medicine and could be something else, medicines law prevails.

Determinations are made by the MHRA's Borderline section, product by product, and a manufacturer or seller can be asked for the product's full composition, presentation and purpose. There is no list of peptides that are medicines and no list that are not. There is a method, and the method weighs claims, format, pharmacology, how the product is used and how widely it is known.

Where a research peptide with no claims stands

Apply the method to a vial of peptide sold to a laboratory with no claims, no instructions, a certificate of analysis and a label that says it is for research. The presentation limb is not met: nothing in the presentation gives an averagely well-informed consumer the impression of a medicine, provided the rest of the site does not undo the label. The function limb is where the honest uncertainty lies. The factors are the substance's pharmacology, the manner in which it is used, the extent of its distribution and its familiarity to consumers. A peptide that is widely known for human use, sold in a single-use vial of the size a person would use, is at some risk of being a medicine by function even with no claim made for it, because three of the four factors point that way. A peptide sold as a milligram quantity of lyophilized powder, with reference data for its characterization and nothing else, has a stronger case that it is a laboratory chemical. The MHRA has never published a determination either way for a research-labeled peptide sold without claims, and this library does not assert one.

What the record does show is that every British action on peptides to date has turned on the presentation limb. The seller or clinic said what the peptide would do.

Twenty years of precedent: melanotan

The United Kingdom's first research-peptide enforcement predates the current market by more than a decade, and it concerned a peptide. From 2008 the MHRA warned that melanotan, sold online and through tanning salons and gyms as a tanning agent, was an unlicensed medicine. In early 2009 the agency said the product was being advertised and sold illegally, that it has not been tested for safety, quality or effectiveness, and that any supplying or advertising of Melanotan is illegal. By September 2013 the agency had received 18 reports detailing 74 separate reactions which are suspected to be side effects linked to the use of Melanotan, and had closed down 72 websites offering to supply Melanotan to UK customers within the last three months. The products were, in the agency's words, offered to people in gyms, beauty and tanning salons, as well as being sold through the Internet.

Melanotan established the pattern the United Kingdom still follows. A peptide with no licence is an unlicensed medicine the moment it is presented for an effect on the body; the agency's instrument is website closure and seizure rather than prosecution of buyers; and the tanning market, which never pretended to be research, was pursued on the presentation limb alone.

The record in 2025 and 2026

The MHRA's Criminal Enforcement Unit reported that in 2025 it seized almost twenty million units of illegally traded medicines with a street value of about £45 million, disrupted more than 1,500 websites and social media accounts marketing illegal products and removed more than 1,200 posts. Sedatives and painkillers made up most of the volume; several thousand products of a class of obesity medicines were among them. The unit's deputy director of enforcement, Andy Morling, put the agency's position in one sentence: I would urge everyone to think very carefully before buying powerful medicines online. If something looks or feels wrong, it probably is.

Operation Pangea XVIII, the annual Interpol-coordinated action against online medicine sales, ran from March 10 to 23, 2026 and was led in the United Kingdom by the MHRA, Border Force and the Department of Health in Northern Ireland. Medicines valued at £4.6 million were intercepted at the border in those fourteen days. In February 2026 the agency executed a series of warrants in Lincolnshire and Nottinghamshire against what it described as an organised network manufacturing and selling unlicensed obesity medicines and peptide products, as reported in the trade press at the time.

Then, on April 4, 2026, the Guardian published an investigation into British clinics selling peptides. It found clinics offering BPC-157, MOTS-c, Cortexin, thymosin alpha-1 and others at several hundred pounds a month, with stated benefits, pricing and course lengths, while describing the products as "research only". On April 15 the MHRA responded: If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012. The MHRA will take action against clinics which are identified as breaching the legal requirements. Some clinics removed the claims after being contacted. The investigation is the first the agency has opened into research-labeled peptides as a category, and its outcome is the thing to watch in the United Kingdom.

Advertising: two regulators, one rule

Advertising an unlicensed medicine breaks regulation 279, enforced by the MHRA. It also breaks the CAP Code enforced by the Advertising Standards Authority, whose rules 12.1 and 12.11 require that medicines hold a licence before they are marketed and that medicinal claims not be made for products without one. The ASA's practice, in rulings on supplements and other borderline products, is that a medicinal claim for an unlicensed product breaches both rules whatever the product is called. A research peptide advertised with a benefit is therefore exposed to two regulators at once, and the ASA's active monitoring of online advertising is, in this market, the more likely first contact.

The border

Import of an unlicensed medicine for sale is a breach of the Regulations, and Border Force detains and refers suspected medicines to the MHRA, which is how most of the Pangea seizures are made. A research peptide arriving as a chemical, for a laboratory, addressed to a business, with a safety data sheet and a certificate, is in a different position from a parcel of vials addressed to a flat with a tanning forum's name on the invoice; the goods may be identical and the paperwork is what distinguishes them. The United Kingdom does not have a scheduling system that makes the substance itself controlled, so the border decision, like the domestic one, turns on presentation and purpose.

Peptides sold as chemicals fall under the chemicals regime as well: the retained REACH and CLP rules on classification, labeling and safety data sheets apply to a substance placed on the market as a chemical. A supplier whose labels and documents meet those rules has, in the process, made the clearest statement available that the product is a chemical and not a medicine.

What is different from the United States, and what is the same

• The test is presentation and function, not intent. American law asks what the seller intends and infers it from everything. British law asks how the product is presented and what it does. In practice the evidence overlaps almost entirely, but the British function limb can reach a product with no claims at all, which the American test cannot without inferring intent.
• Possession is not an offence. The Regulations reach sale, supply and advertising. A buyer is not prosecuted. In the United States personal importation is unlawful in most circumstances; in the United Kingdom the question does not arise in the same way.
• The research label is weighed the same way. The MHRA's own guidance lists "medical research" wording as an implied medicinal claim, and its April 2026 statement makes clinics' "research only" labels irrelevant where claims are made alongside them. In neither country does the label settle anything.
• Enforcement is by website closure and seizure. Seventy-two melanotan sites in 2013, fifteen hundred sites and accounts in 2025. Prosecutions are rare and reserved for manufacturing networks.

What to watch

• The outcome of the MHRA's April 2026 clinic investigation: whether it ends in warnings, closures or the first prosecution of a clinic for research-labeled peptides.
• Whether the MHRA's Borderline section issues any determination on a peptide sold without claims, which would be the first guidance on the function limb in this market.
• ASA rulings naming peptides, which would bring the advertising regulator's active monitoring to bear on the category.
• Whether the February 2026 manufacturing case reaches court, and what the charges say about peptide products as distinct from the obesity medicines.

Frequently asked questions

Are research peptides legal in the UK?

A peptide sold with no medicinal claims and no presentation for use in the body is not a medicine by presentation. Whether it is a medicine by function depends on its pharmacology at the amount sold and on how it is used and known, decided case by case by the MHRA, which has published no determination for a research-labeled peptide. A peptide sold with claims about what it does is an unlicensed medicine, and selling or advertising it is an offence.

Is BPC-157 legal in the UK?

BPC-157 holds no UK marketing authorisation. Sold with claims, as the clinics in the April 2026 investigation sold it, it is an unlicensed medicine. Possessing it is not an offence under the Human Medicines Regulations. Selling or advertising it as a medicine is.

Does labeling a peptide "research only" protect a UK seller?

Not where claims are made alongside it. The MHRA said in April 2026 that clinics making medicinal claims for "research only" peptides are selling medicines, and its guidance lists "medical research" wording itself as an implied medicinal claim.

Can I import peptides into the UK for personal use?

The Regulations do not make possession or personal import an offence; they regulate sale, supply and advertising. Border Force may still detain a parcel it takes to be an unlicensed medicine and refer it to the MHRA. This page describes the law and does not advise anyone to import anything.

Who enforces peptide law in the UK?

The MHRA, through its Borderline section for determinations and its Criminal Enforcement Unit for seizures, website disruption and prosecutions; Border Force at the border; and the Advertising Standards Authority for advertising.

Sources & Further Reading

1. The Human Medicines Regulations 2012, SI 2012/1916: regulation 2(1) (definition of "medicinal product"), regulation 46 (requirement for a marketing authorisation), regulation 279 (prohibition on advertising unauthorised medicinal products).
2. Medicines and Healthcare products Regulatory Agency. Guidance Note 8: A guide to what is a medicinal product. Revised November 2012; see also the MHRA's guidance "Decide if your product is a medicine or a medical device", updated October 20, 2020.
3. Court of Justice of the European Union: Van Bennekom, Case 227/82 (1983); HLH Warenvertriebs and Orthica, Joined Cases C-211/03 and others (2005); Hecht-Pharma, Case C-140/07 (2009).
4. Cancer Research UK, Melanotan injections are illegal and possibly unsafe, January 28, 2009, quoting the MHRA; the FHT blog, "Medicines regulator issues warning against Melanotan", September 13, 2013, quoting the MHRA's statement of August 31, 2013.
5. The Pharmaceutical Journal, Weight-loss drugs among £45m of illegally traded medicines seized in 2025, January 26, 2026, quoting the MHRA; Pharmacy Magazine, "Border operation stops £4.6m of illegal medicines entering UK", March 2026, on Operation Pangea XVIII.
6. The Guardian, "Medicines watchdog to investigate UK peptide clinics over health claims", April 4, 2026; Aesthetics Journal, "MHRA investigates clinics following peptide claims", April 15, 2026, quoting the MHRA statement.
7. Committee of Advertising Practice, The CAP Code, rules 12.1 and 12.11 (medicines, medical devices, health-related products and beauty products).

Cosmic Peptides. (2026, November 1). Research peptides in the United Kingdom: medicines by presentation or by function. Cosmic Peptides Research Library. Retrieved November 1, 2026, from https://cosmicpeptides.com/research/compliance/research-peptides-in-the-united-kingdom

@misc{cosmicpeptides_research_compliance_research_peptides_in_the_united_kingdom,
  author       = {{Cosmic Peptides}},
  title        = {Research peptides in the United Kingdom: medicines by presentation or by function},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance/research-peptides-in-the-united-kingdom},
  urldate      = {2026-11-01},
  note         = {Last reviewed 2026-11-01}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Research peptides in the United Kingdom: medicines by presentation or by function
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/01
UR  - https://cosmicpeptides.com/research/compliance/research-peptides-in-the-united-kingdom
Y2  - 2026/11/01
LA  - en
ER  -